



US005691306A

United States Patent [19]

Bergeron et al.

[11] Patent Number: **5,691,306**[45] Date of Patent: **Nov. 25, 1997**[54] **METHODS OF DETECTION AND TREATMENT OF PROTEIN TRAFFICKING DISORDERS AND INCREASING SECRETORY PROTEIN PRODUCTION**[75] Inventors: **John J. M. Bergeron**, Pointe-Claire; **David Y. Thomas**, Montreal West, both of Canada; **Ikuo Wada**, Sapporo, Japan[73] Assignee: **National Research Council of Canada**, Ottawa, Canada[21] Appl. No.: **296,362**[22] Filed: **Aug. 25, 1994****Related U.S. Application Data**

[63] Continuation-in-part of Ser. No. 112,395, Aug. 26, 1993, abandoned.

[51] Int. Cl.⁶ **A61K 38/00; C07K 7/00**[52] U.S. Cl. **514/11; 435/70.1**[58] Field of Search **514/11; 435/70.1**[56] **References Cited****FOREIGN PATENT DOCUMENTS**WO 93/13788 7/1993 WIPO **A61K 37/00**WO93/13768 7/1993 WIPO **A61K 31/40****OTHER PUBLICATIONS**Ou et al., "Conformational Changes Induced in the Endoplasmic Reticulum Luminal Domain of Calnexin by Mg-ATP in Ca²⁺" *J. Biol. Chem.*, vol. 2(30) pp. 18051-18059 (1995).Volpe et al., "The endoplasmic reticulum-sarcoplasmic reticulum connection: Distribution of endoplasmic reticulum markers in the sarcoplasmic reticulum of skeletal muscle fibers," *Proc. Natl. Acad. Sci. (USA)* 89:6142-6146, 1992.Pelham et al., "Toxin entry: how reversible is the secretory pathway?," *Trends in Cell Biology* 2: 183-185, 1992.Bergeron et al., "Calnexin: a membrane-bound chaperone of the endoplasmic reticulum," *Trends in Biochem. Sci.* 19(3): 124-128, 1994.Ou et al., "Association of folding intermediates of glycoproteins with calnexin during protein maturation," *Nature* 364: 771-776, 1993.Pind et al., "Interaction Of CFTR With The Chaperone P88 (Calnexin) During Biosynthesis In The ER," *FASEB* 7(7): A1245, 1993.David et al., "Interaction with Newly Synthesized and Retained Proteins in the Endoplasmic Reticulum Suggests a Chaperone Function for Human Integral Membrane Protein IP90 (Calnexin)," *Journal of Biological Chemistry* 268(13): 9585-9592, 1993.Wada et al., "SSR α and Associated Calnexin Are Major Calcium Binding Proteins of the Endoplasmic Reticulum Membrane," *Journal of Biological Chemistry* 266: 19599-19610, 1991.Ahluwalia et al., "the p88 Molecular Chaperone Is Identical to the Endoplasmic Reticulum Membrane Protein, Calnexin," *Journal of Biological Chemistry* 267(15): 10914-10918, 1992.Hochstenbach et al., "Endoplasmic reticulum resident protein of 90 kilodaltons associates with the T- and B-cell antigen receptors and major histocompatibility complex antigens during their assembly," *Proc. Natl. Acad. Sci. (USA)* 89: 4734-4738, 1992.Baksh and Michalak, "Expression of Calreticulin in *Escherichia coli* and Identification of Its Ca²⁺ Binding Domains," *Journal of Biological Chemistry* 266(32): 21458-21465, 1991.Degen and Williams, "Participation of a Novel 88-kD Protein in the Biogenesis of Murine Class I Histocompatibility Molecules," *Journal of Cell Biology* 112(6): 1099-1115, 1991.Görlich et al., "The Signal Sequence Receptor Has a Second Subunit and Is Part of a Translocation Complex in the Endoplasmic Reticulum as Probed by Bifunctional Reagents," *Journal of Cell Biology* 111(No.6, Pt.1):2283-2294, 1990.DeVirgilio et al., "CNE1, a *Saccharomyces cerevisiae* Homologue of the Genes Encoding Mammalian Calnexin and Calreticulin," *Yeast* 9: 185-188, 1993.Hawn et al., "Molecular Cloning and Expression and SmIrV1, a *Schistosoma mansoni* Antigen with Similarity to Calnexin, Calreticulin, and OvRa11," *Journal of Biological Chemistry* 268(11):7692-7698, 1993.Huang et al., "Primary Structure and Characterization of an *Arabidopsis thaliana* Calnexin-like Protein," *Journal of Biological Chemistry* 268(9):6560-6566, 1993.Gilchrist and Pierce, "Identification and Purification of a Calcium-binding Protein in Hepatic Nuclear Membranes," *Journal of Biological Chemistry* 268(6): 4291-4299, 1993.Cala et al., "Purification of a 90-kDa Protein (Band VII) from Cardiac Sarcoplasmic Reticulum. Identification as calnexin and localization of casein kinase II phosphorylation sites," *Journal of Biological Chemistry* 268(4): 2969-2975, 1993.Villa et al., "The Endoplasmic Reticulum Of Purkinje Neuron Body And Dendrites: Molecular Identity And Specializations For Ca²⁺ Transport," *Neuroscience* 49(2): 467-477, 1992.Ou et al., "Casein Kinase II Phosphorylation of Signal Sequence Receptor α and the Associated Membrane Chaperone Calnexin," *Journal of Biological Chemistry* 267(33): 23789-23796, 1992.Beckmann et al., "Interaction of Hsp 70 with Newly Synthesized Proteins: Implications for Protein Folding and Assembly," *Science* 248: 850-854, 1990.

(List continued on next page.)

Primary Examiner—Howard E. Schain**Assistant Examiner**—P. L. Touzeau**Attorney, Agent, or Firm**—Seed and Berry LLP[57] **ABSTRACT**

The present invention provides compositions and methods for increasing secretory protein production. In another aspect, the present invention provides compositions for use in methods of treating and diagnosing protein trafficking disorders. These methods generally involve the alteration of calnexin activity to increase protein secretion or retention.

8 Claims, 11 Drawing Sheets

OTHER PUBLICATIONS

- Booth and Koch, "Perturbation of Cellular Calcium Induces Secretion of Luminal ER Proteins," *Cell* 59: 729-737, 1989.
- Bradford, M., "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding," *Analytical Biochemistry* 72: 248-254, 1976.
- Galvin et al., "The major histocompatibility complex class I antigen-binding protein p88 is the product of the calnexin gene," *Proc. Natl. Acad. Sci.(USA)* 89: 8452-8456, 1992.
- Gething and Sambrook, "Protein folding in the cell," *Nature* 355: 33-45, 1992.
- Laemmli, U., "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4," *Nature* 227: 680-685, 1970.
- Wiedmann et al., "A signal sequence receptor in the endoplasmic reticulum membrane," *Nature* 328: 830-833, 1987.
- Walter and Blobel, "Preparation of Microsomal Membranes for Cotranslational Protein Translocation," *Methods in Enzymology* 96: 84-93, 1983.
- Louvard et al., "Antibodies in the Golgi Complex and the Rough Endoplasmic Reticulum," *Journal of Cell Biology* 92: 92-107, 1982.
- Liu et al., "Purification And Characterization Of The Apically Secreted 80 KDa Glycoprotein From Madin-Darby Canine Kidney (MDCK) Cells," *Biochemistry International* 25(1): 109-121, 1991.
- Migliaccio et al., "The Signal Sequence Receptor, Unlike the Signal Recognition Particle Receptor, Is Not Essential for Protein Translocation," *Journal of Cell Biology* 117(1): 15-25 1992.
- Nicchitta et al., "Biochemical Fractionation and Assembly of the Membrane Components That Mediate Nascent Chain Targeting and Translocation," *Cell* 65: 587-598, 1991.
- Prehn et al., "Structure and biosynthesis of the signal-sequence receptor," *European Journal of Biochemistry* 188: 439-445, 1990.
- Rindress et al., "Organelle-specific Phosphorylation. Identification of unique membrane phosphoproteins of the endoplasmic reticulum and endosomal apparatus," *Journal of Biological Chemistry* 268(7): 5139-5147, 1993.
- Suzuki et al., "Regulating the Retention of T-Cell Receptor α Chain Variants within the Endoplasmic Reticulum: Ca^{2+} -dependent Association with BiP," *Journal of Cell Biology* 114(2): 189-205, 1991.
- Valetti et al., "Russels Bodies: A General Response of Secretory Cells to Synthesis of a Mutant Immunoglobulin Which Can Neither Exit from, Nor Be Degraded in, the Endoplasmic Reticulum," *Journal of Cell Biology* 115(4): 983-994, 1991.




FIG. 1a




FIG. 1c




FIG. 1b




FIG.2




FIG. 3a




FIG. 3c




FIG. 3b




FIG.4




FIG. 5a




FIG. 5b

chase (min) 0 2 5 10 20 30 45 60 90 120

0 2 5 10 20 30 45 60 90 120




FIG. 6

5'CGCGGCTCGTGACGGTCGGGCAGCCTCCGCTGCTGTCTCCACTGCAGCGCGGGCCGGGCG 60
 TGCGGGCGGGTGGAGGCGCGGGCCGCGCACGACTCGAGATC ATG GAA GGG AAA TGG CTG 119
 M E G K W L
 -20

CTG TGT ATG TTA CTG GTC CTT GGA ACT ACT ATT GTT CAG GCT CAT GAA GGA 170
 L C M L L V L G T T I V Q A H E G
 -10 -1 1

CAT GAT GAT GAT ATG ATT GAT ATT GAG GAC GAC CTC GAT GAT GTT ATT GAA 221
H D D D M I D I E D D L D D V I E 20
 10

GAG GTA GAA GAC TCC AAA TCA AAA CCA GAT ACC AGC GCT CCT ACA TCT CCA 272
 E V E D S K S K P D T S A P T S P
 30

AAG GTC ACC TAT AAA GCT CCA GTT CCT TCC GGG GAA GTG TAT TTT GCT GAT 323
 K V T Y K A P V P S G E V Y F A D 50
 40

TCC TTT GAC AGA GGA ACT CTG TCA GGG TGG ATT TTA TCA AAA GCC AAG AAG 374
S F D R G T L S G W I L S K A K K 70
 60

GAT GAC ACT GAT GAT GAA ATT GCC AAA TAT GAC GGA AAG TGG GAG GTA GAT 425
 D D T D D E I A K Y D G K W E V D 80

GAA ATG AAG GAA ACA AAG CTC CCA GGT GAT AAA GGG CTT GTG TTG ATG TCT 476
E M K E T K L P G D K G L V L M S 100
 90

CGG GCC AAG CAT CAT GCC ATC TCT GCA AAA CTC AAC AAG CCC TTC CTG TTT 527
R A K H H A I S A K L N K P F L F 120
 110

GAT ACC AAG CCT CTC ATT GTT CAG TAT GAG GTT AAT TTC CAA AAT GGA ATA 578
 D T K P L I V Q Y E V N F Q N G I 130

GAA TGT GGT GGT GCC TAT GTG AAA CTG CTT TCC AAA ACC CCC GAA CTC AAC 629
 E C G G A Y V K L L S K T P E L N 150
 140

FIG.7A

CTG GAT CAG TTC CAC GAC AAG ACC CCT TAT ACG ATT ATG TTT GGT CCA GAT 680
 L D Q F H D K T P Y T I M F G P D
 160 170

AAA TGT GGA GAA GAC TAT AAA CTG CAC TTC ATC TTC CGC CAC AAA AAC CCC 731
 K C G E D Y K L H F I F R H K N P
 180 190

AAA ACA GGC GTA TAT GAA GAA AAG CAT GCT AAG AGG CCA GAT GCA GAT CTG 782
 K T G V Y E E K H A K R P D A D L
 200

AAG ACC TAT TTT ACT GAC AAG AAA ACA CAT CTT TAT ACA TTA ATC TTG AAT 833
 K T Y F T D K K T H L Y T L I L N
 210 220

CCA GAT AAT AGT TTT GAA ATA CTA GTG GAC CAA TCT ATT GTG AAT AGT GGA 884
P D N S F E I L V D Q S I V N S G
 230 240

AAT TTA CTA AAT GAC ATG ACT CCT CCT GTA AAT CCT TCA CGT GAA ATT GAG 935
 N L L N D M T P P V N P S R E I E
 250

GAC CCA GAA GAC CAG AAG CCT GAA GAT TGG GAT GAA AGA CCA AAA ATA CCA 986
 D P E D Q K P E D W D E R P K I P
 260 270

GAT CCT GAT GCT GTC AAA CCA GAT GAC TGG AAT GAA GAT GCC CCT GCT AAG 1037
D P D A V K P D D W N E D A P A K
 280 290

ATT CCA GAT GAA GAA GCT ACG AAG CCT GAT GGC TGG TTA GAT GAT GAA CCC 1088
I P D E E A T K P D G W L D D E P
 300

GAA TAT GTA CCT GAT CCA GAT GCA GAG AAG CCA GAG GAT TGG GAT GAA GAT 1139
E Y V P D P D A E K P E D W D E D
 310 320

FIG.7B

ATG GAT GGA GAA TGG GAG GCT CCT CAG ATC GCC AAC CCT AAG TGT GAG TCG 1190
 M D G E W E A P Q I A N P K C E S
 330 340

GCC CCT GGG TGT GGT GTC TGG CAG CGA CCT ATG ATT GAC AAC CCT AAT TAT 1241
 A P G C G V W Q R P M I D N P N Y
 350 360

AAG GGC AAA TGG AAG CCT CCC ATG ATT GAC AAT CCT AAC TAC CAG GGA ATC 1292
 K G K W K P P M I D N P N Y Q G I
 370

TGG AAA CCC CGG AAG ATA CCA AAT CCG GAT TTC TTT GAA GAT CTG GAA CCT 1343
 W K P R K I P N P D F F E D L E P
 380 390

TTC AAA ATG ACT CCT TTT AGC GCT ATT GGT TTG GAA CTG TGG TCT ATG ACC 1394
 F K M T P F S A I G L E L W S M T
 400 410

TCA GAC ATT TTT TTT GAC AAC TTT ATT GTT TGT GGG GAT CGA AGA GTA GTT 1445
 S D I F F D N F I V C G D R R V V
 420

GAT GAT TGG GCC AAT GAT GGA TGG GGT CTG AAG AAA GCA GCT GAT GGG GCT 1496
 D D W A N D G W G L K K A A D G A
 430 440

GCC GAG CCA GGT GTG GTG GGG CAG ATG ATT GAG GCA GCT GAG GAG CGC CCG 1547
 A E P G V V G Q M I E A A E E R P
 450 460

TGG CTC TGG GTG GTC TAC GTT TTG ACC GTA GCT CTG CCC GTG TTT CTT GTT 1598
 W L W V V Y V L T V A L P V F L V
 470

ATC CTC TTC TGC TGC TCT GGA AAG AAA CAG TCA AGT CCT GTG GAG TAT AAG 1649
 I L F G G S G K K Q S S P V E Y K
 480 490

AAG ACA GAC GCT CCT CAG CCA GAT GTG AAG GAG GAG GAA GAA GAA AAG GAA 1700
 K T D A P Q P D V K E E E E E K E
 500 510

FIG.7C

GAG GAA AAG GAC AAG GGC GAT GAG GAG GAG GAG GGC GAA GAA AAA CTT GAA 1751
E E K D K G D E E E E G E E K L E
520 530

GAG AAG CAA AAA AGT GAT GCT GAA GAA GAT GGC GGC ACT GCC AGT CAA GAG 1802
E K Q K S D A E E D G G T A S Q E
540

GAG GAC GAT AGG AAA CCT AAG GCA GAG GAG GAT GAA ATT TTG AAC AGA TCA 1853
E D D R K P K A E E D E I L N R S
550 560

CCA AGA AAC AGA AAG CCA CGA AGA GAG TGA AACAATTTAAGAACTTGAT 1903
P R N R K P R R E END
570 573

CTGTGATTTCTCTCCCTCCTCCCCTTCCCCTGCAAGCATGGTCCTGGGAGAGGACCTGG 1963
CACACCTTAGGTTGAACTCAGAAAACCTCCAGACATCACCATCAACAGGTTCCAGTCGAA 2023
CACTAGCCCGTGTAATTTTAAACATCTAAGCAGTAAATAATTGCTGTTGTGAAATAAAGG 2083
ACCCTGTTTCTGTAGAAAGAAGGCATATAACATTAATAGTTGTGAAATGTAACATGAAGC 2143
AACTAACTTGTATTTTTTGTGTTTGTGTTTGTGTTTAAACATCTTTGTTTTTAAAATAGAG 2203
TGATAGAACTTTGCCAGTCTTTAAAATCTTGGCTTAATTTAATATATTAATCTGTCCATG 2263
CAGAAATAACACCAACCTTTAGAAATGTTTGGGGGATGAATTGCAGTTTCTATAACCAAA 2323
TTTTTAAGTTTGGTATTATGAAACATTCAAGTGTTCTCTGTCCCTTAAAATTGATAATCA 2383
TTGTTTAAAGTGCAGTCATTTGTGGTTATAGTCTTGTGTTTGTGTTTCCATCACCCAGT 2443
TCCTCCTAAGAAAACCTGAGGAGATGGACTGGATGGAAGCCCAAATTATAAAAGGTTCTGT 2503
TTCAGTTATATTAATAAATAGATATACAGAAAGAAGAACTTTTCTCTTGGTGTGTTGTTA 2563
GACCATACAGTGCGTGTGTTCTGTTGCCCTTGGTAGCAGCTCTGTTCCCAGACGGCTCTG 2623
CAGTCCGTTGAGGAGGTGGTATGATGTGGCATTCCGGCAGTCATGCTTCCACAACCTGGGA 2683
GTGTCCTGGGCTCCAGCCTTCCGGAGCAGGTGGCTGTTTGGAGGAATGCTCCCAGGGCATGG 2743
GAGCTCCCAAGCAGACGCAGATGTTTTCATCACTTCCCTCCACTGTGTTGACACTGTCTCC 2803
TTCCCAGTTGTCCCAGATCCCAGCTTTCTCCTCTGCTATGCATTTTCTTACAGCGCAC 2863
GTTGCAGTCCGTCACTGAAAATGATTATAAGCTCCGCATAGTGTTAAGCTTTATTGTGAT 2923
TAAGTGATGTTTCTTCTTCTTTAAGCAGACCCACACCTTTCCAGGGTCAAAGTACAGG 2983
ATAAGATACTGTCTTTTCAATTTTATCCATTTCTTTTGCTCTGTGTCAAGACTTGAAAAGT 3043
CTCAGCCAGAGGTGAGCCAATTCAGAATCTGTAATTGAACACAGGCTTAAAGTATTT 3' 3100

FIG.7D

**METHODS OF DETECTION AND
TREATMENT OF PROTEIN TRAFFICKING
DISORDERS AND INCREASING
SECRETORY PROTEIN PRODUCTION**

**CROSS-REFERENCE TO RELATED
APPLICATION**

This application is a continuation-in-part application to Ser. No. 08/112,395, filed Aug. 26, 1993, now abandoned.

TECHNICAL FIELD

The present invention is generally directed toward methods of treating and diagnosing protein trafficking disorders and altering secretory protein production. More specifically, the present invention is directed toward compositions and methods of treating and diagnosing protein trafficking disorders and altering secretory protein production by controlling calnexin activity.

BACKGROUND OF THE INVENTION

The endoplasmic reticulum (ER) functions in the translocation of proteins, cleavage of signal peptides, protein folding, core glycosylation, assembly of oligomers, degradation of misfolded secretory proteins, and storage of calcium in the cell. It facilitates these activities through the use of a number of different enzymes and "molecular chaperones." BiP is a known molecular chaperone in the ER's luminal pathway. However, the futile search for an association of secretory proteins in HepG2 cells with BiP has provided a strong indicia that more than one pathway is present (Lodish, *J. Biol. Chem.* 263:2107-2110, 1988). To date, efforts to elucidate the second pathway deemed the "membrane pathway" have been unsuccessful.

Elucidation of the nature of the membrane pathway and its components is of primary importance to treatment of protein trafficking disorders such as cystic fibrosis, juvenile pulmonary emphysema, Tay-Sachs disease, congenital sucrose isomaltase deficiency, and familial hypercholesterolaemia. These protein trafficking disorders and others may be caused by alteration of any aspect of the translocation assembly, or the proteins associated therewith, causing them to be inappropriately retained in the ER.

In view of the lack of current therapies to successfully control all protein trafficking disorders, it is evident that there exists a need for new and additional therapeutic agents and methods to treat these disorders. The present invention fulfills these needs, and further provides other related advantages.

SUMMARY OF THE INVENTION

The present invention is generally directed towards methods of treating and diagnosing protein trafficking disorders and controlling secretory protein production.

In one aspect, the present invention involves methods of increasing secretory protein production in a biological preparation, comprising administering a calnexin suppressor agent to a biological preparation in an amount effective to increase secretory protein production.

Another aspect of the present invention involves agents which decrease calnexin associations for use in the manufacture of a medicament for increasing secretory protein production in a warm-blooded animal.

Another aspect of the present invention involves compositions that include an agent which decrease calnexin activ-

ity for use in the manufacture of a medicament for treating a warm-blooded animal for protein trafficking disorders which require reduction of calnexin associations.

Another aspect of the present invention involves compositions that include an agent which stimulates calnexin activity for use in the manufacture of a medicament for treating a warm-blooded animal for a protein trafficking disorder which require stimulation of calnexin associations.

Another aspect of the present invention involves conjugates comprising agents linked to moieties which target the conjugates to the endoplasmic reticulum for use in the manufacture of a medicament for treating a warm-blooded animal for a protein trafficking disorder.

Another aspect of the present invention involves methods of diagnosing a protein trafficking disorder in a warm-blooded animal, comprising exposing an anticalnexin antibody, containing a reporter group, to the ER of a warm-blooded animal under conditions and for a time sufficient to permit binding to calnexin, and detecting the amount of calnexin and determining therefrom the presence of a protein trafficking disorder.

Another aspect of the present invention involves methods of diagnosing a protein trafficking disorder in a biological preparation, comprising exposing an anticalnexin antibody, containing a reporter group, to the biological preparation under conditions and for a time sufficient to permit binding to calnexin, and detecting the amount of calnexin and determining therefrom the presence of a protein trafficking disorder.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth which describe in more detail certain procedures and/or compositions, and are hereby incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 Association of newly synthesized proteins with calnexin in HepG2 cells.

FIG. 1a. HepG2 cells were labeled with 50 μ Ci/ml Trans 35 S-label for 30 minutes followed by lysis and immunoprecipitation with anti- α 1-antitrypsin antibody (lanes 1 and 2) and either untreated (lane 1) or treated (lane 2) with endo H. Cell lysates were immunoprecipitated with anti-calnexin antibody under denaturing (lane 3) or non-denaturing conditions (lane 4). After immunoprecipitation with anti-calnexin antibody under non-denaturing conditions, coprecipitated proteins were eluted from protein A-agarose beads with SDS. Sequential immunoprecipitations were carried out with anti- α 1-antitrypsin (lane 5); anti- α 1-antichymotrypsin (lane 6); anti-transferrin (lane 7); anti-C3 (lane 8); anti-apo β -100 (lane 9); anti- α -fetoprotein (lane 10) and anti-albumin antibodies (lane 11). Lysates immunoprecipitated directly with anti-albumin antibody revealed a major band corresponding to the expected mobility of albumin (lane 12.)

FIG. 1b. HepG2 cells were incubated at 37° C. in the presence of 10 μ g/ml tunicamycin for 3 h., and then labeled with 50 μ Ci/ml Trans 35 S-label for 10 minutes in the presence (lanes 2, 4 and 6) of 10 μ g/ml tunicamycin (Boehringer Mannheim). Lanes 1, 3, 5 did not receive tunicamycin treatment. The cell lysates were immunoprecipitated with anti- α 1-antitrypsin (lanes 1 and 2); anti-transferrin (lanes 3 and 4); and anti-calnexin (lanes 5, 6) under non-denaturing conditions. Immunoprecipitates were analyzed by SDS-PAGE. The mobilities of molecular mass markers (duping EN) are indicated to the left of the gels.

FIG. 2. Sucrose density gradient fractionation of calnexin-associated proteins. HepG2 cells without (a, c, e, and g) or with tunicamycin treatment for 3 h (b, d, f, and h) were radiolabeled for 10 minutes and then lysed in 2% cholate/HBS buffer. After centrifugation (100,000×g, 20 minutes), supernatants were loaded onto a 5%-30% (w/v) sucrose density gradient containing 50 mM Hepes-NaOH, pH 7.5, 0.2M NaCl, 0.3% cholate and centrifuged at 180,000×g for 15 h. Fractions were immunoprecipitated under non-denaturing conditions with anti-calnexin (a and b), anti- α 1-antitrypsin (c and d) or anti-albumin antibodies (e and f). g and h are immunoblots of the fractions probed with anti-calnexin antibody.

FIG. 3. Kinetics of association of newly synthesized secretory proteins with calnexin in HepG2 cells.

FIG. 3a. HepG2 cells were labeled with 50 μ Ci/ml Trans 35 S-label for 10 minutes, and chased in DMEM, 1 mM methionine, 0.5 mM cysteine for the indicated times. Cell lysates were immunoprecipitated with anti-calnexin antibody under non-denaturing conditions.

FIG. 3b. Following pulse chase, cell lysates were immunoprecipitated with anti- α 1-antitrypsin antibody (upper panel) to determine the kinetics of intracellular transport; (lower panel), after cell lysates were immunoprecipitated with anti-calnexin antibody calnexin-associated proteins were eluted and sequentially immunoprecipitated with anti- α 1-antitrypsin antibody as described in length to FIG. 1. The immunoprecipitates were treated with (left) or without (right) endo H at 37° for 15 h.

FIG. 3c. Following pulse chase, cell lysates were immunoprecipitated with anti-calnexin antibody under non-denaturing conditions. After elution of the calnexin-associated proteins, sequential immunoprecipitations were carried out with anti- α 1-antitrypsin (O-O), anti-transferrin (C—C), anti-C3 antibodies (Δ — Δ). The immunoprecipitates were analyzed by SDS-PAGE followed by fluorography. The intensity of the bands corresponding to the respective proteins were quantitated by densitometry (Zeineh soft laser scanning densitometer interfaced with an IBM PC using GS 350 Data System (Hoefer Scientific Instruments)) and expressed as a percentage of the maximum association found.

FIG. 4. Time course of the association of newly synthesized proteins with calnexin in the presence of Azc. HepG2 cells were incubated with 5 mM azetidine-2-carboxylic acid (Azc) (Sigma) in methionine-free medium containing 10% dialyzed FCS for 60 minutes, then pulse labeled with 50 μ Ci/ml Trans 35 S-label for 10 minutes in the presence of 5 mM Azc and chased in the absence of the drug. At the indicated times, cells were harvested, lysed, and immunoprecipitated with anti-calnexin antibody under non-denaturing conditions as in FIG. 1. Immunoprecipitates were analyzed on an 8% SDS-PAGE gel followed by fluorography. The mobility of albumin would correspond to that of the 69 kDa marker.

FIG. 5. Association of incompletely folded transferrin with calnexin.

FIG. 5a. HepG2 cells were pulse labeled for 10 minutes with 50 μ Ci/ml Trans 35 S-label and chased for the indicated times. Transferrin was immunoprecipitated from cell lysates with anti-transferrin antibody, and analyzed on reducing (upper panel) or non-reducing gels (lower panel) as described by Lodish et al. *J. Biol. Chem.* 266:14835-14838 (1991).

FIG. 5b. HepG2 cells were pulse labeled and chased for the indicated times. Total cell lysates were immunoprecipi-

tated with anti-calnexin antibody. Calnexin-associated proteins were eluted from the protein A-agarose beads with SDS and sequentially immunoprecipitated with anti-transferrin antibody as described in the legend to FIG. 1. The higher order aggregates of transferrin are not calnexin associated (cf. a, b, lower panels). They are presumed to represent interchain disulfide bonds and their significance as folding intermediates or misfolded products (Kim et al., *J. Cell Biol.* 118:541-549 (1992)) is unknown.

FIG. 6. Selectivity of calnexin for incompletely folded glycoproteins. Shortly after translocation, glycosylated proteins are presented to calnexin via oligosaccharyl transferase where protein folding, catalyzed by protein folding enzymes, occurs coincident with glycoprotein dissociation from calnexin (membrane associated pathway). Tunicamycin treatment prevents presentation to calnexin and may lead to protein misfolding and BiP association or folding by other ER luminal chaperones and secretion. Non-glycosylated proteins, e.g., albumin, are presented directly to the ER lumen where soluble resident chaperones may organize their folding with ER luminal protein folding enzymes.

FIGS. 7A-7D. A representative Calnexin DNA sequence as disclosed in Wada et al., *J. Biol. Chem.*, 266(29):19599-19610 (1991).

DETAILED DESCRIPTION OF THE INVENTION

Prior to setting forth this invention it may be helpful to first define certain terms that will be used herein.

"Protein trafficking disorder" refers to a disorder which affects secretory protein translocation, folding, or assembly in the ER. Representative examples of protein trafficking disorders include familial hypercholesterolaemia, cystic fibrosis, Tay-Sachs disease, congenital sucrose isomaltase deficiency, and juvenile pulmonary emphysema.

"Secretory protein" refers to all N-linked glycosylated proteins and unfolded proteins processed through the ER, including all coagulation factors, all blood factors, all hormone and growth factor receptors and all ion channels including, by way of example, cystic fibrosis chloride channels and there are nicotinic and muscarinic acetylcholine receptors.

"Biological preparation" refers to any animal cell or tissue ex vivo. Suitable preparations include, by way of example, HepG2 cells, COS cells, 293 cells, and ATT20 cells.

"Molecular chaperone" refers to the class of proteins which stabilize unfolded or partially folded structures, prevent the formation of inappropriate intra- or interchain interactions, or interact with protein molecules to promote the rearrangement of protein-protein interactions in oligomeric structures.

"Calnexin association" refers to the association, including covalent and non-covalent binding, of calnexin to a secretory protein.

The present invention provides methods and compositions directed to the regulation of secretory protein production and the treatment and diagnosis of protein trafficking disorders. The membrane pathway of the endoplasmic reticulum (ER) constitutes both a quality control and a translocation apparatus. Specifically, this apparatus is designed to ensure the functional integrity of secretory proteins and regulate their transport through the membrane. It is comprised of a complex of four integral membrane proteins, a phosphoprotein (pp90), a phosphoglycoprotein (pgp35), and two non-phosphorylated glycoproteins (gp25H

and gp25L). The latter three proteins have been identified as signal sequence receptors SSR α (pgp35), SSR β (gp25H), and a non-phosphorylated glycoprotein (gp25L). The phosphoprotein (pp90) represents calnexin. (The calnexin sequence is elucidated in FIG. 7.)

Secretory proteins are divided between the luminal and membrane pathways by glycosylation. Glycosylation of nascent proteins leads to presentation to the membrane pathway while non-glycosylated proteins apparently follow the luminal pathway. (FIG. 6). Under normal conditions, some glycoproteins fold more rapidly on the membrane associated pathway with tunicamycin treatment leading to misfolding and inhibition of the rate of protein transport.

Calnexin is a molecular chaperone which selectively associates in a transient fashion with newly synthesized monomeric glycoproteins and is thus active in the membrane pathway. Calnexin associates with glycoproteins and incompletely folded secretory proteins. Dissociation of glycoproteins from calnexin occurs at different rates and is related to the time taken for their folding. This results in large differences and the rates of transport from the ER to the Golgi apparatus, with the rate limiting step governed by the time spent in the ER in association with calnexin.

Calnexin, as molecular chaperone in the membrane pathway, is thus distinguishable from BiP, as a molecular chaperone in the luminal pathway. (FIGS. 1, 2, and 6). The differences are demonstrated by stress treatment. Stress conditions, such as heat shock or tunicamycin treatment, greatly stimulate the interaction of BiP with substrate proteins. However, neither treatment stimulates the association of calnexin with substrate proteins. In addition, BiP associated proteins usually form aggregates, whereas calnexin associated proteins do not. This can be observed by sucrose gradient centrifugation. (FIG. 2).

Only incompletely folded intermediates of transferrin, devoid of interchain disulphide bonds, are associated with calnexin although the interchain disulphide bonded species existed after maturation. (FIG. 4a). Such interchain aggregates have been observed in other studies on proteins folding in vivo and under defined conditions have been shown to be BiP associated. Thus, calnexin recognizes different features in secretory proteins that those recognized by BiP.

As noted above, one aspect of the present invention concerns increasing production of secretory proteins in either a biological preparation or a warm-blooded animal. As disclosed in the present invention, increase in the release of secretory proteins from the ER can be controlled by regulation of calnexin activity.

Any one of several techniques may be used to detect which secretory proteins are in association with calnexin including those described in detail in Harlow, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory (1988), incorporated herein by reference. By way of example, suitable methods include immunoprecipitation, followed by peptide mapping and protein sequencing. (FIGS. 1, 2, and 3). Briefly, this entails pulse chasing cells and then immunoprecipitating, employing an anti-calnexin antibody. Anti-calnexin antibodies can be identified using any one of several techniques known in the art, e.g., those described in the Harlow (cited above).

Confirmation of specific interaction may be subsequently accomplished by dissociation of the coimmunoprecipitate with SDS and reprecipitation with secretory protein specific antibody. This technique is described in detail in Harlow, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory (1988). However, when employing this tech-

nique it is important to use the appropriate detergent in precipitation. Suitable detergents include, by way of example, cholate, deoxycholate, digitonin and CHAPS to preserve the interaction, strong detergents, such as Triton X-100 and SDS, tend to destroy the interaction.

Calnexin associations may also be demonstrated or detected by cross-linking with bifunctional agents. This technique is especially for those interested in MHC1 and T cell receptors and is described in detail in Ahluwalia, *J. Biol. Chem.* 267:10914-10918 (1992); Degen, *J. Cell Biol.* 112:1099-1115 (1991); Hochstenbach, *Proc. Natl. Acad. Sci. USA* 89:4734-4738 (1992); Galvin, *Proc. Natl. Acad. Sci. USA* 89:8452-8456 (1992).

Calnexin associations may also be demonstrated or detected using in vitro transcription and translation of cDNAs with translocation into microsomal vesicles to experimentally examine associated proteins with the endogenous calnexin present in these vesicles. This technique can be used to easily monitor secretory proteins for their potential to associate with calnexin.

Secretory proteins in transient association (i.e., those which are released after folding) with calnexin include, by way of example, α 1-antitrypsin, α 1-antichymotrypsin, transferrin, apo β -100, complement 3 (C3), gp80 human complement-associated protein, and α -fetoprotein.

Secretory proteins retained, i.e., delaying their release into the luminal pathway, by calnexin in the ER include the unassembled T-cell receptor subunits, acetylcholine receptor subunits, HMG CoA reductase, murine class 1 histocompatibility protein (MHC1) (prior to association with β 2 microglobulin), and H2a subunit of asialoglycoprotein receptor and any mutant or misfolded glycoproteins. Misfolded or mutant glycoproteins are retained by calnexin and are ultimately degraded by ER resident proteases or transported to lysosomes for degradation.

Suppression of calnexin associations increases the rate of release of secretory proteins. Secretory proteins in transient association with calnexin are translocated through the membrane more quickly. Those which would ordinarily be retained by calnexin are released directly through the luminal pathway.

Calnexin associations can be suppressed using a "calnexin suppressor agent" which, in the context of the present invention, refers to any agent which functions to disrupt or inhibit calnexin associations with secretory proteins using any suitable means including calcium depletion, genetic manipulation, calnexin blocking antibodies, and insertion of antisense sequences. Suitable calnexin suppressor agents for specific secretory problems may be selected by any one of several means, including immobilizing calnexin either by direct lining or by biotinylation and binding to streptavidin to a column and then to use this to interact in vitro with secretory proteins, thereby establishing the binding parameters and any necessary cofactors for the release of proteins. These techniques are described in detail in Harlow, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory (1988). Alternatively, the changing secretory protein presence due to calnexin associations may be evaluated in the biological preparation by immunoprecipitation of the specific secretory protein before and after the administration of the particular calnexin suppressing agent employed.

In one embodiment of the present invention, the calnexin suppressor agent acts by calcium depletion in the cytoplasm, or more preferably, in the ER. This can be accomplished using any suitable agent including an ionophore, such as valinomycin or nonactin, or a calcium channel blocker, such as verapamil, nifedipine or diltiazem.

In another embodiment of the present invention, calnexin associations are suppressed by administering to the biological preparation or warm-blooded animal a suitable glycosylation inhibitor, including by way of example, tunicamycin, castanospermine, nojirromycin, deoxynojirramycin, or swainsonine.

In another aspect of the present invention, calnexin associations are suppressed by decreasing the temperature of the biological preparation to about 30° C. For example, the retention of CFTR Δ F508, which depends on calnexin for folding and translocation, is temperature sensitive. Reducing the temperature of the cell line to 30° C. allows the CFTR Δ F508 channel to get to the plasma membrane, presumably by altering the association with calnexin. This technique is described in detail in Pind, *J. Biol. Chem.* 269:12784-12788 (1994).

In another aspect of the present invention, calnexin associations are suppressed by introducing an agonist or antagonist which will competitively inhibit binding of the unfolded secretory proteins. Suitable inhibitors include by way of example, amino acid analogues which incorporate into glycoproteins and produce unfolded proteins under in vivo conditions, such as azetidine-2-carboxylic acid. Calnexin recognizes these analogues, enters into association with them, and then are essentially incapacitated because they are unable to fold and subsequently release them.

In another aspect of the present invention, calnexin suppression is accomplished by treatment of cells with dithiothreitol or diamide to inhibit dissociation of secretory proteins from calnexin. This technique is described in detail in Wada, *J. Biol. Chem.* 269(10):7464-72 (1994).

An increase of secretory protein production, and hence the success of the method of calnexin suppressor agent, can be monitored using any one of several techniques, including evaluating the changing secretory protein presence in the biological preparation by immunoprecipitation of the specific secretory protein before and after the administration of the particular calnexin suppressing agent employed. This technique, and other suitable techniques, are described in detail in Harlow, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory (1988).

Another aspect of the present invention involves a method of treating protein trafficking disorders. Protein trafficking disorders may be treated by suppressing or stimulating calnexin activity depending upon the etiology of the particular disorder.

For example, a warm-blooded animal suffering from a protein trafficking disorder would benefit from the suppression of calnexin activity if the disorder is one in which an otherwise biologically active protein is retained in the ER. Such disorders can be identified by an underproduction of secretory protein recognized by coimmuno-precipitation assays as described in Ou et al., *Nature* 364:771-776 (1993) and include, by way of example, familial hypercholesterolaemia (class 2 mutations in the LDL receptor), cystic fibrosis (CFTR Δ F508), Tay-Sachs disease, congenital sucrase isomaltase deficiency, and juvenile pulmonary emphysema.

Secretory proteins which are retained by calnexin within the ER may aggregate therein or be subject to degradation. These proteins may be identified by coimmunoprecipitation assays as described in Ou et al., *Nature* 364:771-776 (1993) and include, by way of example, acetylcholine receptor subunits, HMG CoA reductase, calnexin selectively binds mutant proteins, including, by way of example, α 1-antitrypsin, LDL receptors, b-hexosaminidase, CFTR

and influenza haemagglutinin and, more specifically, the Z mutation as well as the null Hong Kong mutation of α 1-antitrypsin. The interaction of CFTR and the prolonged association of the DF508 mutant protein has been demonstrated and a model is that this association is responsible for the retention of this otherwise functional channel in the ER (Pind, *J. Biol. Chem.* 269: 12784-12788 (1994)).

Calnexin activity can be suppressed by any one of several suitable techniques, including administering a therapeutically effective amount of any one of the calnexin suppressor agents described in detail above. A therapeutically effective amount is determined based on in vitro experiments, followed by in vivo studies.

The calnexin suppressor agents may be administered by injection, infusion, orally, rectally, lingually, or transdermally. Depending on the mode of administration, the compounds or separate components can be formulated with the appropriate diluents and carriers to form of ointments, creams, foams, and solutions.

Injection may be intravenous, intramuscular, intracerebral subcutaneous, or intraperitoneal. For injection or infusion, the compound would be in the form of a solution or suspension. It would be dissolved or suspended in a physiologically compatible solution in a therapeutically effective amount.

For oral administration, the compounds may be in capsule, table, oral suspension, or syrup form. The tablet or capsules would contain a suitable amount to it comply with the general and preferred ratios set forth below. The capsules would be the usual gelatin capsules and would contain, in addition to the three compounds, a small quantity of magnesium stearate or other excipient.

Tablets would contain the a therapeutically effective amount of the compound and a binder, which may be a gelatin solution, a starch paste in water, polyvinyl pyrrolidone, polyvinyl alcohol in water or any other suitable binder, with a typical sugar coating.

Syrup would contain a therapeutically effective amount of the compound.

A warm-blooded animal suffering from a protein trafficking disorder which would benefit from calnexin stimulation can be identified by coimmunoprecipitation as described in detail in Ou et al., *Nature* 364:771-776 (1993) and include, by way of example, viral cancers and other viral infections. The assembly of functional viral particles requires viral glycoproteins which are processed through the secretory pathway. This has been confirmed with VSV G protein and influenza HA protein in Hammond et al., *Proc. Natl. Acad. Sci. USA* 91(3):913-7 (1994) and in the case of HIV gp120. The HIV gp120 is slowly translocated through the ER because of its long association with the calnexin. Calnexin stimulating agents may prevent the disassociation of HIV gp120, trapping it in the ER.

In order to suppress the production of the viral particles, calnexin activity is stimulated by the administration of a therapeutically effective amount of a phosphorylating agent. Suitable phosphorylating agents include: casein kinase II, cdc2 kinase, and protein kinase C. A therapeutically effective amount may be determined based on in vitro experiments, followed by in vivo studies.

Depending on the mode of administration, the calnexin stimulating agents can be formulated with the appropriate diluents and carriers to form suitable ointments, creams, foams, and solutions as described above. Methods of administration are the same as those outlined above.

The term "treatment" as used within the context of the present invention, refers to reducing or alleviating symp-

toms in a subject, preventing symptoms from worsening or progressing, inhibition or elimination of the causative agent, or prevention of the infection or disorder in a subject who is free therefrom. Thus, for example, treatment of infection includes destruction of the infecting agent, inhibition of or interference with its growth or maturation, neutralization of its pathological effects and the like. A disorder is "treated" by partially or wholly remedying the deficiency which causes the deficiency or which makes it more severe. An unbalanced state disorder is "treated" by partially or wholly remedying the imbalance which causes the disorder or which makes it more severe.

Within another aspect of the present invention, methods are provided for delivering vector constructs to a warm-blooded animal or biological preparation, wherein the vector construct directs the expression of calnexin, or calnexin lacking in cytosolic or transmembrane domains, thereby acting as a calnexin suppressor agent or a calnexin stimulating agent.

As utilized within the context of the present invention, "vector construct" refers to an assembly which directs the expression of a gene of interest. The vector construct must include promoter elements, and a sequence which, when transcribed, is operably linked to the gene of interest and acts as a translation initiation sequence. The vector construct may also include a signal which directs poly-adenylation, one or more selectable markers, as well as one or more restriction sites.

Calnexin cDNA may be prepared as the gene of interest by obtaining either in full length or truncated mutants cloned from mammalian cDNA using any one of several methods described in Sambrook et al., *Molecular Cloning: A Laboratory Handbook*, Cold Springs Harbor Press (1989). In the context of the present invention, the gene of interest is composed of a portion of the gene encoding calnexin which, when expressed, would disrupt the normal functioning of calnexin, by way of example. Such a vector may serve to disrupt calnexin associations in both or either of its function of translocation and retention. It functions as a calnexin suppressor agent in any one of several ways, including, by way of example, by introducing vectors containing gene sequences designed to reduce the rate limiting step of association and folding for secretory proteins. Such sequences might include one which is lacking the cytosolic domain. It would act as a calnexin stimulating agent by the introduction of vectors which encode additional calnexin sequences, thereby increasing the production and decreasing the rate of secretory protein production.

A wide variety of methods may be utilized in order to deliver vector constructs of the present invention to a warm-blooded animal or biological preparation. For example, within one embodiment of the invention, the vector construct is inserted into a retroviral vector, which may then be administered directly into a warm-blooded animal or biological preparation. Representative examples of suitable retroviral vectors and methods are described in more detail in the following U.S. patents and patent applications, all of which are incorporated by reference herein in their entirety: "DNA constructs for retrovirus packaging cell lines," U.S. Pat. No. 4,871,719; "Recombinant Retroviruses with Amphotropic and Ecotropic Host Ranges," PCT Publication No. WO 90/02806; and "Retroviral Packaging Cell Lines and Processes of Using Same," PCT Publication No. WO 89/07150.

Vector constructs may also be carried by a wide variety of other viral vectors, including for example, recombinant

vaccinia vectors (U.S. Pat. Nos. 4,603,112 and 4,769,330), recombinant pox virus vectors (PCT Publication NO. WO 89/01973), poliovirus (Evans et al., *Nature* 339:385-388, 1989; and Sabin, *J. Biol. Standardization* 1:115-118, 1973); influenza virus (Luytjes et al., *Cell* 59:1107-1113, 1989; McMichael et al., *N. Eng. J. Med* 309:13-17, 1983; and Yap et al., *Nature* 273:238-239, 1978); adenovirus (Berkner, *Biotechniques* 6:616-627, 1988; Rosenfeld et al., *Science* 252:431-434, 1991); adeno-associated virus (Samulski et al., *J. Vir.* 63:3822-3828, 1989; Mendelson et al., *Viol.* 166:154-165, 1988); herpes (Kit, *Adv. Exp. Med. Biol.* 215:219-236, 1989); and HIV (Poznansky, *J. Virol.* 65:532-536, 1991).

In addition, vector constructs may be administered to warm-blooded animals or biological preparations utilizing a variety of physical methods, such as lipofection (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417, 1989), direct DNA injection (Acsadi et al., *Nature* 352:815-818, 1991); microprojectile bombardment (Williams et al., *PNAS* 88:2726-2730, 1991); liposomes (Wang et al., *PNAS* 84:7851-7855, 1987); CaPO₄ (Dubensky et al., *PNAS* 81:7529-7533, 1984); or DNA ligand (Wu et al., *J. Biol. Chem.* 264:16985-16987, 1989).

A therapeutic amount may be determined by in vitro experimentation followed by in vivo studies.

Yet another aspect of the present invention concerns a method of treating protein trafficking disorders by targeting a suitable calnexin suppressor agent, calnexin stimulating agent, or any other agent designed to monitor calnexin associations and secretory protein production. For the purposes of illustrating this aspect of the invention, "targeting moiety" refers to any polypeptide molecule from a dipeptide up to, and including, any protein or protein containing compound or any functional equivalent, including those without an amino acid basis, that binds to a desired target site. In a preferred embodiment of the present invention, this method is utilized to deliver calcium depletion agents directly to the ER.

Suitable targeting moieties include any moiety which specifically binds to a cell surface receptor preferably an ER membrane receptor and is capable of affecting the protein trafficking pathway. Suitable targeting moieties include proteins, peptides, and non-proteinaceous molecules. Representative examples of suitable targeting moieties include antibody and antibody fragments; peptides such as bombesin, gastrin-releasing peptide, cell adhesion peptides, substance P, neuromedin-B, neuromedin-C and metenkephalin; hormones, including EGF, alpha- and beta-TGF, estradiol, neurotensin, melanocyte stimulating hormone, follicle stimulating hormone, luteinizing hormone, and human growth hormone; proteins corresponding to ligands for known cell surface receptors, including low density lipoproteins, transferrin and insulin; fibrinolytic enzymes; and biological response modifiers, including interleukin, interferon, erythropoietin and colony stimulating factor also constitute targeting moieties of this invention. Moreover, analogs of the above targeting moieties that retain the ability to specifically bind to a cell surface receptor, preferably an ER membrane receptor, are suitable targeting moieties. Essentially any analog having about the same affinity as a target moiety, herein specified, could be used in synthesis of receptor modulators.

In a preferred embodiment, the targeting moiety is an antibody or antibody fragment. Particularly preferred antibodies include monoclonal antibodies having high specificity for an ER membrane receptor and the ability to catalyze

the internalization of the conjugate. Suitable antibodies may be selected by assays for internalization known in the art and described in detail in *Cancer Treat. Res.* 68:23, 1993; *Leuk. Lymp.* 9:293, 1993; *Anticancer Drug Des.* 7:427, 1992 (incorporated herein by reference). An anti-calnexin antibody can be produced by methods well known in the art and described in Harlow et al., *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory (1988), incorporated herein by reference. The immunoconjugate comprises at least one agent coupled to an anti-calnexin antibody. A single or multiple molecules of one type of agent may be coupled to an antibody. Alternatively, more than one type of agent may be coupled to an antibody.

The basic requirement of the targeting moiety is that the polypeptide increase the specificity of the therapeutic agent toward the desired site, either in vivo and in vitro, depending on the application. Thus, the targeting polypeptides can include proteins having certain biological activities rendering them specific for desired sites.

Suitable targeting polypeptides include but are not limited to receptors, hormones, lymphokines, growth factors, substrates, particularly compounds binding to surface membrane receptors. Suitable receptors include surface membrane receptors, antibodies, enzymes, naturally occurring receptors, lectins, and the like. Of particular interest are immunoglobulins or their equivalents.

The targeting moiety may be readily labeled or conjugated to a wide variety of molecules, including for example, toxins, fluorescent molecules, magnetic resonance enhancers, and radionuclides. Representative examples of toxins include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, pokeweed antiviral protein, tritin, Shigella toxin, and Pseudomonas exotoxin A. Representative examples of fluorescent molecules include fluorescein, phycoerythrin, rodamine, Texas red and luciferase. Representative examples of radionuclides include Cu-64, Ga-67, Ga-68, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-111, I-123, I-125, I-131, Re-186, Re-188, Au-198, Au-199, Pb-203, At-211, Pb-212 and Bi-212. Methods for labeling or conjugating the targeting moiety to any of the above described compounds or compositions may be readily accomplished by one of ordinary skill in the art given the disclosure provided herein (see also Trichothecene Antibody Conjugate, U.S. Pat. No. 4,744,981; Antibody Conjugate, U.S. Pat. No. 5,106,951; Fluorogenic Materials and Labeling Techniques, U.S. Pat. No. 4,018,884; Metal Radionuclide Labeled Proteins for Diagnosis and Therapy, U.S. Pat. No. 4,897,255; and Metal Radionuclide Chelating Compounds for Improved Chelation Kinetics, U.S. Pat. No. 4,988,496; see also Inman, *Methods in Enzymology*, Vol. 34, *Affinity Techniques, Enzyme Purification: Part B*, Jakoby and Wichek (eds.), Academic Press, New York, P. 30, 1974; see also Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988).

A calnexin suppressor or stimulating agent may be coupled to, i.e., covalently bonded to, the targeting moiety either directly or via a linker group. It will be evident to those of ordinary skill in the art that a variety of bifunctional reagents may be employed as the linker group. A preferred method is described in U.S. Pat. No. 5,094,848 (the '848 patent), incorporated herein by reference. Briefly, the '848 patent discloses a method of binding a therapeutic agent by a cleavable diphosphate or amidated diphosphate linkage to a protein specific for the targeting site, guiding the therapeutic agent directly to the targeted site. The conjugate so created possesses the ability to selectively deliver one or more agents to the ER.

The conjugate is administered in a therapeutically effective amount in a suitable excipient. The effective amount for a particular conjugate may be determined based on in vitro experiments followed by in vivo studies. Depending on the mode of administration, the complex can be formulated with the appropriate diluents and carriers to form ointments, creams, foams, and solutions. Methods of administration are identical to those outlined above.

In another aspect of the present invention, the a targeting moiety conjugated to a reporting group may be used to detect protein trafficking disorders. By administering a warm-blooded animal or a biological preparation an effective amount of such a conjugate, wherein the agent is a reporter group, such as a radionuclide or magnetic resonance enhancer, and detecting the level of the reporter group, the level of calnexin activity can be ascertained.

The effective amount of conjugate necessary may be determined based upon in vitro experiments, followed by in vivo studies. The step of detecting a radionuclide is typically performed with an imaging camera using a detector appropriate for the particular radionuclides type of emission. These techniques are described in detail in Harlow et al., *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory (1988), incorporated herein by reference. The step of detecting a magnetic resonance imaging enhancer is likewise well known in the art.

By detecting the levels of calnexin in the warm-blooded animals or biological preparation using these well-known techniques and the disclosure herein, those of ordinary skill in the art will be able to gauge calnexin levels and identify protein trafficking disorders or the risk thereof.

The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLES

EXAMPLE 1

Antibody Production

Rabbit antibodies were raised to a synthetic peptide corresponding to the C-terminus of calnexin, i.e., residues 555-573 plus a cysteine residue at the carboxyl terminus (Multiple Peptide Systems, San Diego, Calif.). The peptide was conjugated to keyhole limpet hemacyanin using the cross-linker succinimidyl-4-P-maleimidophenyl butyrate (SMPB) (Pierce). Specific antibodies to the calnexin peptide were purified from the antiserum with peptide-affinity columns. HepG2 cells were preincubated with methionine-free DMEM containing 10% dialyzed FGS for 30 minutes, and then labeled with 50 μ Ci/ml Tran³⁵S-label (ICN) in methionine-free media for 30 minutes. Cells were rinsed twice with cold PBS and once with HBS (50 mM HEPES-NaOH (pH. 7.5), 200 mM NaCl). For non-denaturing immunoprecipitations, cells were lysed in HBS buffer containing 2% sodium cholate, 1 mM PMSF, 5 μ g/ml each of aprotinin and leupeptin. Cell lysates were precleared with preimmune serum and Pansorbin (Calbiochem). Affinity purified anti-calnexin was added to the supernatant 2h, (4° C.) followed by protein A-agarose (Calbiochem) and rotated for 1 h at 4° C. Beads were washed three times with HBS containing 0.5% cholate and once with HBS. For immunoprecipitations under denaturing conditions, cells were lysed in HBS containing 1% SGS, lysates were heated in boiling water for 5 minutes and passed 15 times through a 27 gauge needle. After centrifugation, the supernatants were diluted with 10 volumes of HBS containing 1% Triton X-100, and

immunoprecipitated with anti-calnexin as described above, except that the HBS washing buffer contained 1% Triton X-100, 0.5% deoxycholate (DOC) and 0.1% SDS. Sequential immunoprecipitations were carried out first under non-denaturing conditions as described above. 0.2 ml HBS containing 1% SDS was then added to the protein A-agarose beads and heated at 90° C. for 3 minutes followed by the addition of 2 ml of HBS containing 1% Triton X-100. After centrifugation, the supernatant was used for a second immunoprecipitation with specific antibodies to proteins secreted by HepG2 cells (Calbiochem) as indicated above. Immune-complexes were recovered with protein A-agarose, and washed three times with HBS containing Triton X-100, 0.5% DOC, and 0.1 SDS. All immunoprecipitates were analyzed in 7% or 8% SDS-PAGE gels followed by treatment with Enhance (DuPont NEN).

EXAMPLE 2

Association of Secretory Glycoproteins with Calnexin

This example demonstrates the association of secretory glycoproteins with calnexin.

HepG2 cells which have been labeled with Tran³⁵S-label for 30 minutes followed by cell lysis and incubation with antibodies to α 1-antitrypsin, both the 52 kDa ER form and the 55 kDa Golgi form of α 1-antitrypsin were precipitated with only the former being sensitive to endo H (FIG. 1a, lanes 1,2). Quantitations revealed that ca. 50% of the α 1-antitrypsin had reached terminal glycosylating compartments of the Golgi apparatus during this labeling period. Immunoprecipitation of cell lysates under denaturing conditions with affinity purified antibodies raised either to residues 555-573 of calnexin (FIG. 1a, lane 3) or residues 487-505 only precipitated calnexin.

However, when immunoprecipitations were carried out with calnexin antibody under non-denaturing conditions, several proteins were coprecipitated (FIG. 1a, lane 4). The major coprecipitated proteins migrated with mobilities of 52 kDa, 66 kDa, 74 kDa, 175 kDa, and ca. 230 kDa (calnexin migrates at 90 kDa). The ER forms of the major secretory glycoproteins of HepG2 cells correspond to similar mobilities, i.e., α 1-antitrypsin, 52 kDa; α 1-antichymotrypsin, 52 kDa; α -fetoprotein, 66 kDa; transferrin, 74 kDa; C3, 175 kDa; apo β -100, ca. 230 kDa. This observation predicts that most of the major secretory glycoproteins in HepG2 cells are capable of binding to calnexin. To test this, we designed a sequential immunoprecipitation protocol to identify calnexin associated proteins as described in the legend to FIG. 1.

Following immunoprecipitation with anti-calnexin in the presence of cholate, the calnexin associated proteins (FIG. 1a, lane 4) were eluted with SDS followed by immunoprecipitation under denaturing conditions with antibodies specific to the respective secretory proteins (FIG. 1a, lanes 5-11). Remarkably, α 1-antitrypsin, α 1-antichymotrypsin, transferrin, C3 apo β -100, and α -fetoprotein were found to be coimmunoprecipitated with calnexin. Albumin was not immunoprecipitated from the calnexin eluted proteins (FIG. 1a, lanes 11) although anti-albumin antibodies clearly precipitated the protein from total cell lysates (lane 12). Quantitation revealed that after 10 minutes of radiolabeling, 25% of newly synthesized α 1-antitrypsin, 30% of transferrin and 30% of C3 were coprecipitated with calnexin. As the efficiency of total cellular calnexin immunoprecipitation under these conditions was only 60%, we conclude that at

least 50% of each of the newly synthesized secretory glycoproteins were calnexin associated.

However, radiolabeled calnexin was not detected in immunoprecipitates with antibodies to the secretory glycoproteins (see FIG. 1b, lanes 1, 3) because calnexin has a relatively long half-life ($t^{1/2}$ >24 h) and is not efficiently radiolabeled during a short labeling period. Thus, these newly synthesized secretory glycoproteins enter the ER and bind with high efficiency to preexisting calnexin.

EXAMPLE 3

Specificity of Calnexin

The non-glycosylated major secretory protein of HepG2 cells, albumin, was not associated with calnexin, yet the related glycosylated protein α -fetoprotein was, suggesting that only glycoproteins may bind to calnexin. The glycosylation inhibitor tunicamycin was used to evaluate if proteins were selected for association with calnexin because of their N-linked glycosylation. Tunicamycin addition to cells led to the inhibition of glycosylation of α 1-antitrypsin and transferrin (FIG. 1b, lanes 1,3 cf. lanes 2,4) and these as well as most other proteins were not coimmunoprecipitated with calnexin (FIG. 1b, cf. lanes 5,6). That only glycoproteins associated with calnexin was also demonstrated by the adsorption of calnexin eluted proteins to Concanavalin-A Sepharose. The major polypeptides associated with calnexin were those which bound to Concanavalin-A Sepharose while calnexin (itself not a glycoprotein) was not bound.

In order to evaluate if newly synthesized glycoproteins were binding with calnexin or formed part of a larger network, the sedimentation properties of calnexin associated glycoproteins were assessed. Sucrose density gradients of lysates of cells labeled for 10 minutes with or without tunicamycin were centrifuged to neat equilibrium. Fractions were collected and immunoprecipitated with anti-calnexin (FIGS. 2a, b), anti- α 1-antitrypsin (FIGS. 2c, d) and anti-albumin antibodies (FIGS. 2e, f). The distribution of the radiolabeled calnexin associated proteins was compared to that of calnexin as determined by immunoblot analysis of the fractions (FIGS. 2g, h). In control cells (without tunicamycin), most calnexin (FIG. 2g) is found in fractions 3, 4 which also contain majority of the radiolabeled proteins associated with calnexin (FIG. 2a, lanes 3,4). The highest level of calnexin associated α 1-antitrypsin (52 kDa, FIGS. 2a, c) was found in fractions 2, 3 while transferrin (74 kDa, FIG. 2a) was predominantly in fractions 3, 4; C3 (175 kDa) was in fractions 4, 5 and apo β -100 (\approx 230 kDa) in fractions 5, 6. Hence, calnexin associated glycoproteins of greater molecular mass separated from those of lower mass as would be expected for individual associations of each glycoprotein with calnexin (there were exceptions; for example, glycoproteins of 28, 30, 35 kDa which we have not identified were found in lanes 3-5 of FIG. 2a) indicating that they form part of a large complex.

The majority of newly synthesized radiolabeled calnexin found in fraction 2 (FIG. 2a) did not correspond to the sedimentation of the majority of calnexin as determined by immunoblot (fraction 3, FIG. 2g) showing that newly synthesized glycoproteins associated with pre-existing calnexin which was not radiolabeled. After tunicamycin treatment most calnexin associations were abolished with the sedimentation of calnexin itself being slightly affected (cf. g, h) now having a distribution close to that of newly synthesized calnexin (b cf. h). The sedimentation of the 52 kDa band which coimmunoprecipitates with calnexin (FIG. 2a) cor-

respond to that of α 1-antitrypsin (FIG. 2c) which itself showed an increased sedimentation in sucrose gradients of lysates from tunicamycin treated cells despite a lower mass of the protein (48 kDa, FIG. 2d). By contrast, newly synthesized albumin (unassociated with calnexin) showed similar sedimentation properties whether from control (FIG. 2e) or tunicamycin treated cells (FIG. 2f). Hence, no large network of ER proteins was responsible for the calnexin associations.

EXAMPLE 4

Kinetics of Calnexin Association with Newly Synthesized Glycoproteins as Compared to Endo H Resistance

Pulse-chase studies (FIG. 3a) demonstrated the transient association of newly synthesized proteins with calnexin. However, some proteins dissociated from calnexin more quickly than others. By sequential immunoprecipitation (see legend to FIG. 1), the $t^{1/2}$ of α 1-antitrypsin association (52 kDa) with calnexin was determined to be 5 minutes (FIG. 2b, lower panel). Transferrin was associated with calnexin with a $t^{1/2}$ of ca. 35 minutes (FIG. 3c), while C3 showed an association with calnexin with a $t^{1/2}$ of 25 minutes (FIG. 3c) as did apo β -100 ($t^{1/2}$ ca. 25 minutes). For all the proteins tested, maximal binding to calnexin did not appear immediately after the pulse but only after 2–20 minutes of chase. This delay can be explained by the time needed to complete the translation of nascent polypeptide chains (14) with larger proteins (e.g., C3, 175 kDa) requiring a longer time for completion than smaller proteins such as α 1-antitrypsin (52 kDa).

The acquisition of endo H resistance was used as a measure of the time taken by secretory proteins for ER to Golgi transport. α 1-antitrypsin entered Golgi terminal glycosylating compartments as early as 10 minutes with a $t^{1/2}$ of ca. 20 minutes observed (FIG. 3b, upper panel). For C3, a $t^{1/2}$ of 60 minutes was found and for transferrin entry was as early as 30 minutes but the $t^{1/2}$ of acquisition of endo H resistance was extraordinarily long, i.e., >120 minutes. Therefore, there was a differential lag period between the dissociation of these glycoproteins from calnexin and the acquisition of endo H resistance.

EXAMPLE 5

Association of Misfolded and Incompletely Folded Glycoproteins with Calnexin

The different times of association of glycoproteins with calnexin may be related to their different rates of folding in the ER. Only incompletely folded proteins were tested to determine if calnexin was associated thereto. Two experi-

mental approaches were followed. In the first, the incorporation of the proline analogue, azetidine-2-carboxylic acid (Azc) into proteins was used to interfere with their folding. This has been used previously to demonstrate stable association of proteins with the cytosolic chaperone HSP72 (Beckman et al., *Science* 248:850–854). In HepG2 cells, pulse labeled in the presence of Azc and chased for various times in the absence of the analogue, newly synthesized proteins remained bound to calnexin (FIG. 4). Albumin in Azc treated cells still did not associate with calnexin. Thus, the association of newly synthesized proteins with calnexin depends on their glycosylation but misfolded glycoproteins once bound are released much more slowly.

The second approach directly examined whether calnexin associates only with incompletely folded glycoproteins during normal protein maturation. Lodish and Kong, *J. Biol. Chem.* 266:14835–14838 (1991), have defined conditions to distinguish incompletely folded intermediates during transferrin maturation in the ER of HepG2 cells. They used non-reducing gels to measure the differences in the mobilities of transferrin during disulfide bond rearrangement (there are 19 disulfide bonds in transferrin (Morgan et al., *J. Biol. Chem.* 260:14739–14801 (1985))). After pulse labeling and chase, transferrin immunoprecipitates revealed in reducing gels a sharp band of 74 kDa (FIG. 5a, upper) which was endo H sensitive. On non-reducing gels (FIG. 5a, lower), the major portion of transferrin migrated as a broad, diffuse set of bands at early times of chase (2–20 minutes). This represents the incompletely folded forms of transferrin (c. Gradually, these broad bands were chased to a faster migrating sharper band corresponding to the ER folded form of transferrin with a uniform species of disulfide bonds (Lodish et al., *J. Biol. Chem.* 266:14835–14838 (1991)). Quantitation revealed that ca. 50% of the pulse-labeled transferrin was folded after 30 minutes of chase. The form of transferrin which is in association with calnexin was determined by sequential immunoprecipitation. Transferrin associated with calnexin migrates as a single sharp band on reducing gels (FIG. 5b, upper) but in non-reducing gels (FIG. 5b, lower) only the broad band which represents incompletely folded transferrin is seen. No completely folded transferrin was found in association with calnexin even after 30 minutes of chase. Some aggregates of transferrin were also observed over the time course of the chase (FIG. 1a, lower), but these were not associated with calnexin (FIG. 5b, lower). Hence, calnexin only associates with incompletely folded intermediates of transferrin during maturation but not with aggregated molecules.

From the foregoing it will be evident that although specific embodiments of the invention have been described herein for the purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i i i) NUMBER OF SEQUENCES: 2

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3100 base pairs

(B) TYPE: nucleic acid

-continued

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: cDNA

(i x) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 102..1883

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGCGGCTCGT	GACGGTCGGG	CAGCCTCCGC	TGCTGTCTCC	ACTGCAGCGC	GGGCCGGGCG		60
TGCGGGGCGGG	TGGAGGCGCG	GGCCGCGCAC	GACTCGAGAT	C ATG GAA GGG AAA			113
				Met Glu Gly Lys			
				1			
TGG CTG CTG TGT ATG TTA CTG GTC CTT GGA ACT ACT ATT GTT CAG GCT							161
Trp Leu Leu Cys Met Leu Leu Val Leu Gly Thr Thr Ile Val Gln Ala							
5 10 15 20							
CAT GAA GGA CAT GAT GAT GAT ATG ATT GAT ATT GAG GAC GAC CTC GAT							209
His Glu Gly His Asp Asp Asp Met Ile Asp Ile Glu Asp Asp Leu Asp							
25 30 35							
GAT GTT ATT GAA GAG GTA GAA GAC TCC AAA TCA AAA CCA GAT ACC AGC							257
Asp Val Ile Glu Glu Val Glu Asp Ser Lys Ser Lys Pro Asp Thr Ser							
40 45 50							
GCT CCT ACA TCT CCA AAG GCT ACC TAT AAA GCT CCA GTT CCT TCC GGG							305
Ala Pro Thr Ser Pro Lys Ala Thr Tyr Lys Ala Pro Val Pro Ser Gly							
55 60 65							
GAA GTG TAT TTT GCT GAT TCC TTT GAC AGA GGA ACT CTG TCA GGG TGG							353
Glu Val Tyr Phe Ala Asp Ser Phe Asp Arg Gly Thr Leu Ser Gly Trp							
70 75 80							
ATT TTA TCA AAA GCC AAG AAG GAT GAC ACT GAT GAT GAA ATT GCC AAA							401
Ile Leu Ser Lys Ala Lys Lys Asp Asp Thr Asp Asp Glu Ile Ala Lys							
85 90 95 100							
TAT GAC GGA AAG TGG GAG GTA GAT GAA ATG AAG GAA ACA AAG CTC CCA							449
Tyr Asp Gly Lys Trp Glu Val Asp Glu Met Lys Glu Thr Lys Leu Pro							
105 110 115							
GGT GAT AAA GGG CTT GTG TTG ATG TCT CGG GCC AAG CAT CAT GCC ATC							497
Gly Asp Lys Gly Leu Val Leu Met Ser Arg Ala Lys His His Ala Ile							
120 125 130							
TCT GCA AAA CTC AAC AAG CCC TTC CTG TTT GAT ACC AAG CCT CTC ATT							545
Ser Ala Lys Leu Asn Lys Pro Phe Leu Phe Asp Thr Lys Pro Leu Ile							
135 140 145							
GTT CAG TAT GAG GTT AAT TTC CAA AAT GGA ATA GAA TGT GGT GGT GCC							593
Val Gln Tyr Glu Val Asn Phe Gln Asn Gly Ile Glu Cys Gly Gly Ala							
150 155 160							
TAT GTG AAA CTG CTT TCC AAA ACC CCC GAA CTC AAC CTG GAT CAG TTC							641
Tyr Val Lys Leu Leu Ser Lys Thr Pro Glu Leu Asn Leu Asp Gln Phe							
165 170 175 180							
CAC GAC AAG ACC CCT TAT ACG ATT ATG TTT GGT CCA GAT AAA TGT GGA							689
His Asp Lys Thr Pro Tyr Thr Ile Met Phe Gly Pro Asp Lys Cys Gly							
185 190 195							
GAA GAC TAT AAA CTG CAC TTC ATC TTC CGC CAC AAA AAC CCC AAA ACA							737
Glu Asp Tyr Lys Leu His Phe Ile Phe Arg His Lys Asn Pro Lys Thr							
200 205 210							
GGC GTA TAT GAA GAA AAG CAT GCT AAG AGG CCA GAT GCA GAT CTG AAG							785
Gly Val Tyr Glu Glu Lys His Ala Lys Arg Pro Asp Ala Asp Leu Lys							
215 220 225							
ACC TAT TTT ACT GAC AAG AAA ACA CAT CTT TAT ACA TTA ATC TTG AAT							833
Thr Tyr Phe Thr Asp Lys Lys Thr His Leu Tyr Thr Leu Ile Leu Asn							
230 235 240							
CCA GAT AAT AGT TTT GAA ATA CTA GTG GAC CAA TCT ATT GTG AAT AGT							881
Pro Asp Asn Ser Phe Glu Ile Leu Val Asp Gln Ser Ile Val Asn Ser							
245 250 255 260							

-continued-

GGA Gly	AAT Asn	TTA Leu	CTA Leu	AAT Asn 265	GAC Asp	ATG Met	ACT Thr	CCT Pro	CCT Pro 270	GTA Val	AAT Asn	CCT Pro	TCA Ser	CGT Arg 275	GAA Glu	929
ATT Ile	GAG Glu	GAC Asp	CCA Pro 280	GAA Glu	GAC Asp	CAG Gln	AAG Lys	CCT Pro 285	GAA Glu	GAT Asp	TGG Trp	GAT Asp	GAA Glu 290	AGA Arg	CCA Pro	977
AAA Lys	ATA Ile	CCA Pro 295	GAT Asp	CCT Pro	GAT Asp	GCT Ala	GTC Val 300	AAA Lys	CCA Pro	GAT Asp	GAC Asp	TGG Trp 305	AAT Asn	GAA Glu	GAT Asp	1025
GCC Ala 310	CCT Pro	GCT Ala	AAG Lys	ATT Ile	CCA Pro	GAT Asp 315	GAA Glu	GAA Glu	GCT Ala	ACG Thr	AAG Lys 320	CCT Pro	GAT Asp	GGC Gly	TGG Trp	1073
TTA Leu 325	GAT Asp	GAT Asp	GAA Glu	CCC Pro 330	GAA Glu	TAT Tyr	GTA Val	CCT Pro	GAT Asp 335	CCA Pro	GAT Asp 335	GCA Ala	GAG Glu	AAG Lys	CCA Pro 340	1121
GAG Glu	GAT Asp	TGG Trp	GAT Asp	GAA Glu 345	GAT Asp	ATG Met	GAT Asp	GGA Gly	GAA Glu 350	TGG Trp	GAG Glu	GCT Ala	CCT Pro	CAG Gln 355	ATC Ile	1169
GCC Ala 360	AAC Asn	CCT Pro	AAG Lys 360	TGT Cys	GAG Glu	TCG Ser	GCC Ala	CCT Pro 365	GGG Gly	TGT Cys	GGT Gly	GTC Val	TGG Trp 370	CAG Gln	CGA Arg	1217
CCT Pro 375	ATG Met	ATT Ile	GAC Asp	AAC Asn	CCT Pro	AAT Asn	TAT Tyr 380	AAG Lys	GGC Gly	AAA Lys	TGG Trp	AAG Lys 385	CCT Pro	CCC Pro	ATG Met	1265
ATT Ile 390	GAC Asp	AAT Asn	CCT Pro	AAC Asn	TAC Tyr	CAG Gln 395	GGA Gly	ATC Ile	TGG Trp	AAA Lys	CCC Pro	CGG Arg 400	AAG Lys	ATA Ile	CCA Pro	1313
AAT Asn 405	CCG Pro	GAT Asp	TTC Phe	TTT Phe	GAA Glu 410	GAT Asp	CTG Leu	GAA Glu	CCT Pro	TTC Phe 415	AAA Lys	ATG Met	ACT Thr	CCT Pro	TTT Phe 420	1361
AGC Ser 425	GCT Ala	ATT Ile	GGT Gly	TTG Leu	GAA Glu 425	CTG Leu	TGG Trp	TCT Ser	ATG Met 430	ACC Thr	TCA Ser	GAC Asp	ATT Ile	TTT Phe 435	TTT Phe	1409
GAC Asp 440	AAC Asn	TTT Phe	ATT Ile 440	GTT Val	TGT Cys	GGG Gly	GAT Asp	CGA Arg 445	AGA Arg	GTA Val	GTT Val	GAT Asp	GAT Asp 450	TGG Trp	GCC Ala	1457
AAT Asn 455	GAT Asp	GGA Gly 455	TGG Trp	GGT Gly	CTG Leu	AAG Lys	AAA Lys 460	GCA Ala	GCT Ala	GAT Asp	GGG Gly 465	GCT Ala 465	GCC Ala	GAG Glu	CCA Pro	1505
GGT Gly 470	GTG Val	GTG Val	GGG Gly	CAG Gln	ATG Met	ATT Ile 475	GAG Glu	GCA Ala	GCT Ala	GAG Glu 480	GAG Glu 480	CGC Arg	CCG Pro	TGG Trp	CTC Leu	1553
TGG Trp 485	GTG Val	GTC Val	TAC Tyr	GTT Val	TTG Leu 490	ACC Thr	GTA Val	GCT Ala	CTG Leu 495	CCC Pro	GTG Val	TTT Phe	CTT Leu	GTT Val 500	ATC Ile	1601
TCT Ser	TTC Phe	TGC Cys	TGC Cys	TCT Ser 505	GGA Gly	AAG Lys	AAA Lys	CAG Gln	TCA Ser 510	AGT Ser	CCT Pro	GTG Val	GAG Glu	TAT Tyr 515	AAG Lys	1649
AAG Lys 520	ACA Thr	GAC Asp	GCT Ala 520	CCT Pro	CAG Gln	CCA Pro	GAT Asp 525	GTG Val 525	AAG Lys	GAG Glu	GAG Glu	GAA Glu 530	GAA Glu 530	GAA Glu	AAG Lys	1697
GAA Glu 535	GAG Glu	GAA Glu	AAG Lys 535	GAC Asp	AAG Lys	GGC Gly	GAT Asp 540	GAG Glu	GAG Glu	GAG Glu	GAG Glu	GGC Gly 545	GAA Glu 545	GAA Glu	AAA Lys	1745
CTT Leu 550	GAA Glu	GAG Glu	AAG Lys	CAA Gln	AAA Lys	AGT Ser 555	GAT Asp	GCT Ala	GAA Glu	GAA Glu	GAT Asp 560	GGC Gly 560	GGC Gly	ACT Thr	GCC Ala	1793
AGT Ser 565	CAA Gln	GAG Glu	GAG Glu	GAC Asp	GAT Asp 570	AGG Arg	AAA Lys	CCT Pro	AAG Lys	GCA Ala 575	GAG Glu 575	GAG Glu	GAT Asp	GAA Glu	ATT Ile 580	1841

-continued

TTG AAC AGA TCA CCA AGA AAC AGA AAG CCA CGA AGA GAG TGAAACAATT	1890
Leu Asn Arg Ser Pro Arg Asn Arg Lys Pro Arg Arg Glu	
585 590	
TTAAGAACTT GATCTGTGAT TTCCTCTCCC TCCTCCCCTT CCCCTGCAAG CATGGTCCTG	1950
GGAGAGGACC TGGCACACCT TAGGTTGAAC TCAGAAAACC TCCAGACATC ACCATCAACA	2010
GGTTCCAGTC GAACACTAGC CCGTGTAATT TTAAACATCT AAGCAGTAAA TAATTGCTGT	2070
TGTGAAATAA AGGACCCTGT TTGTGTAGAA AGAAGGCATA TAACATTAAT AGTTGTGAAA	2130
TGTAACATGA AGCAACTAAC TTGTATTTTT TGTTTTGT TTGTTTTTAAA CATCTTTGTT	2190
TTTTAAAATA GAGTGATAGA ACTTTGCCAG TCTTTAAAAT CTGGGCTTAA TTTAATATAT	2250
TAATCTGTCC ATGCAGAAAT AACACCAACC TTTAGAAATG TTTGGGGGAT GAATTGCAGT	2310
TTCTATAACC AAATTTTTTAA GTTTGGTATT ATGAAACATT CAAGTGTCT CTGTCCCTTA	2370
AAATTGATAA TCATTGTTTA AAGTGCAGTC ATTTGTGGTT ATAGTCTTGT TTTGCTTGCT	2430
TCCATCACCC AGTTCCTCCT AAGAAAACCTG AGGAGATGGA CTGGATGGAA GCCCAAATTA	2490
TAAAAGGTTT TGTTCAGTT ATATTAATAA TAGATATACA GAAAGAAGAA ACTTTTCCTC	2550
TTGGTGTGG TTAGACCATA CAGTGCCTGT GTTCTGTTC CCTTGGTAGC AGCTCTGTTC	2610
CCAGACGGCT CTGCAGTCCG TTGAGGAGGT GGTATGATGT GGCATTCGGG CAGTCATGCT	2670
TCCACAACCTG GGAGTGTCTG GGCTCCAGCC TTCCGGAGCA GGTGGCTGTT TGAGGAATGC	2730
TCCCAGGGCA TGGGAGCTCC CAAGCAGACG CAGATGTTTT CATCACTTCC TCCACTGTGT	2790
TGACACTGTC TCCTTCCCAG TTGTCCCAGA TCCCAGCTT TCTCCTCTGC TATGCATTTT	2850
CTTCACAGCG CACGTTGCAG TCCGTCCTG AAAATGATTA TAAGCTCCGC ATAGTGTTAA	2910
GCTTTATTGT GATTAAGTGT ATGTTTCTTC CTTCTTTAAG CAGACCCACA CCTTTCCAGG	2970
GTCAAAGTAC AGGATAAGAT ACTGTCTTTC ATTTTTATCC ATTTCTTTTG CTCTGTGTCA	3030
AGACTTGAAA AGTCTCAGCC AGAGGTGAGC CAATTCAGAA TCTGTAATTG AACACAGGCT	3090
TAAAGTATTT	3100

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 593 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Glu	Gly	Lys	Trp	Leu	Leu	Cys	Met	Leu	Leu	Val	Leu	Gly	Thr	Thr
1				5					10					15	
Ile	Val	Gln	Ala	His	Glu	Gly	His	Asp	Asp	Asp	Met	Ile	Asp	Ile	Glu
			20					25					30		
Asp	Asp	Leu	Asp	Asp	Val	Ile	Glu	Glu	Val	Glu	Asp	Ser	Lys	Ser	Lys
		35					40					45			
Pro	Asp	Thr	Ser	Ala	Pro	Thr	Ser	Pro	Lys	Ala	Thr	Tyr	Lys	Ala	Pro
	50					55					60				
Val	Pro	Ser	Gly	Glu	Val	Tyr	Phe	Ala	Asp	Ser	Phe	Asp	Arg	Gly	Thr
65					70				75						80
Leu	Ser	Gly	Trp	Ile	Leu	Ser	Lys	Ala	Lys	Lys	Asp	Asp	Thr	Asp	Asp
				85					90					95	
Glu	Ile	Ala	Lys	Tyr	Asp	Gly	Lys	Trp	Glu	Val	Asp	Glu	Met	Lys	Glu
			100					105					110		

-continued

Thr	Lys	Leu	Pro	Gly	Asp	Lys	Gly	Leu	Val	Leu	Met	Ser	Arg	Ala	Lys
		115					120					125			
His	His	Ala	Ile	Ser	Ala	Lys	Leu	Asn	Lys	Pro	Phe	Leu	Phe	Asp	Thr
	130					135					140				
Lys	Pro	Leu	Ile	Val	Gln	Tyr	Glu	Val	Asn	Phe	Gln	Asn	Gly	Ile	Glu
145					150					155					160
Cys	Gly	Gly	Ala	Tyr	Val	Lys	Leu	Leu	Ser	Lys	Thr	Pro	Glu	Leu	Asn
				165					170					175	
Leu	Asp	Gln	Phe	His	Asp	Lys	Thr	Pro	Tyr	Thr	Ile	Met	Phe	Gly	Pro
			180					185					190		
Asp	Lys	Cys	Gly	Glu	Asp	Tyr	Lys	Leu	His	Phe	Ile	Phe	Arg	His	Lys
		195					200					205			
Asn	Pro	Lys	Thr	Gly	Val	Tyr	Glu	Glu	Lys	His	Ala	Lys	Arg	Pro	Asp
	210					215					220				
Ala	Asp	Leu	Lys	Thr	Tyr	Phe	Thr	Asp	Lys	Lys	Thr	His	Leu	Tyr	Thr
225					230					235					240
Leu	Ile	Leu	Asn	Pro	Asp	Asn	Ser	Phe	Glu	Ile	Leu	Val	Asp	Gln	Ser
				245					250					255	
Ile	Val	Asn	Ser	Gly	Asn	Leu	Leu	Asn	Asp	Met	Thr	Pro	Pro	Val	Asn
			260					265					270		
Pro	Ser	Arg	Glu	Ile	Glu	Asp	Pro	Glu	Asp	Gln	Lys	Pro	Glu	Asp	Trp
		275					280					285			
Asp	Glu	Arg	Pro	Lys	Ile	Pro	Asp	Pro	Asp	Ala	Val	Lys	Pro	Asp	Asp
	290					295					300				
Trp	Asn	Glu	Asp	Ala	Pro	Ala	Lys	Ile	Pro	Asp	Glu	Glu	Ala	Thr	Lys
305					310					315					320
Pro	Asp	Gly	Trp	Leu	Asp	Asp	Glu	Pro	Glu	Tyr	Val	Pro	Asp	Pro	Asp
				325					330					335	
Ala	Glu	Lys	Pro	Glu	Asp	Trp	Asp	Glu	Asp	Met	Asp	Gly	Glu	Trp	Glu
			340					345					350		
Ala	Pro	Gln	Ile	Ala	Asn	Pro	Lys	Cys	Glu	Ser	Ala	Pro	Gly	Cys	Gly
		355					360					365			
Val	Trp	Gln	Arg	Pro	Met	Ile	Asp	Asn	Pro	Asn	Tyr	Lys	Gly	Lys	Trp
	370					375					380				
Lys	Pro	Pro	Met	Ile	Asp	Asn	Pro	Asn	Tyr	Gln	Gly	Ile	Trp	Lys	Pro
385					390					395					400
Arg	Lys	Ile	Pro	Asn	Pro	Asp	Phe	Phe	Glu	Asp	Leu	Glu	Pro	Phe	Lys
				405					410					415	
Met	Thr	Pro	Phe	Ser	Ala	Ile	Gly	Leu	Glu	Leu	Trp	Ser	Met	Thr	Ser
			420					425					430		
Asp	Ile	Phe	Phe	Asp	Asn	Phe	Ile	Val	Cys	Gly	Asp	Arg	Arg	Val	Val
		435					440					445			
Asp	Asp	Trp	Ala	Asn	Asp	Gly	Trp	Gly	Leu	Lys	Lys	Ala	Ala	Asp	Gly
	450					455						460			
Ala	Ala	Glu	Pro	Gly	Val	Val	Gly	Gln	Met	Ile	Glu	Ala	Ala	Glu	Glu
465					470					475					480
Arg	Pro	Trp	Leu	Trp	Val	Val	Tyr	Val	Leu	Thr	Val	Ala	Leu	Pro	Val
				485					490					495	
Phe	Leu	Val	Ile	Ser	Phe	Cys	Cys	Ser	Gly	Lys	Lys	Gln	Ser	Ser	Pro
			500					505					510		
Val	Glu	Tyr	Lys	Lys	Thr	Asp	Ala	Pro	Gln	Pro	Asp	Val	Lys	Glu	Glu
		515					520					525			
Glu	Glu	Glu	Lys	Glu	Glu	Glu	Lys	Asp	Lys	Gly	Asp	Glu	Glu	Glu	Glu
	530					535					540				

-continued

Gly	Glu	Glu	Lys	Leu	Glu	Glu	Lys	Gln	Lys	Ser	Asp	Ala	Glu	Glu	Asp
545					550					555					560
Gly	Gly	Thr	Ala	Ser	Gln	Glu	Glu	Asp	Asp	Arg	Lys	Pro	Lys	Ala	Glu
				565					570					575	
Glu	Asp	Glu	Ile	Leu	Asn	Arg	Ser	Pro	Arg	Asn	Arg	Lys	Pro	Arg	Arg
			580					585					590		

Glu

We claim:

1. A method of increasing secretory protein production in an ex vivo biological preparation, comprising:
 - administering a calnexin suppressor agent to a biological preparation in an amount effective to increase secretory protein production.
2. The method of claim 1 wherein said agent acts by depleting calcium.
3. The method of claim 2 wherein said agent is an ionophore.
4. The method of claim 3 wherein said agent is chosen from the group consisting of valinomycin and nonactin.
5. The method of claim 2 wherein said agent is a calcium channel blocker.
6. The method of claim 5 wherein said agent is chosen from the group consisting of verapamil, nifedipine, and diltiazem.
7. The method of claim 1 wherein said agent increases the production of a secretory protein selected from the group consisting of a coagulation factor, a blood factor, a hormone receptor, and an ion channel.
8. The method of claim 1 wherein said agent increases the production of a secretory protein selected from the group consisting of α 1-antitrypsin; α 1-antichymotrypsin; α -fetoprotein; transferrin; Complement 3 (C3); and apo β -100.

* * * * *